Roper Technologies (ROP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva/Gazyvaro in primary membranous nephropathy, highlighting late stage pipeline momentum. See our latest analysis for Roche Holding. Roche Holding’s CHF330.2 share price follows a 5.33% 90 day share price return and a 32.83% 1 year total shareholder return, suggesting recent FDA and diagnostics news is feeding into building...

Roche Holding shares have delivered a 35.0% return over the past three years, and the stock now screens as undervalued on market multiples with a high value score, raising the question of whether the current price still offers a margin of safety. A 35.0% gain over three years suggests Roche Holding has already rewarded patient shareholders, so fresh buyers need to consider how much of the story is already reflected in the price. Positive late stage data for oncology and kidney disease...

Roche Holding (SWX:ROP) has introduced the cobas HDV test, described as the first fully automated, high throughput assay for Hepatitis D Virus detection. The test is designed to support improved diagnosis and monitoring of Hepatitis D, which is considered the most aggressive form of viral hepatitis. The launch targets a major unmet clinical need and is intended to support laboratories as new HDV treatments become available. For investors tracking Roche Holding, the cobas HDV launch adds a...